A Phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of TP53 Mutant Myelodysplastic Syndromes

Aprea Therapeutics AB0 sites154 target enrollmentStarted: July 12, 2019Last updated: February 7, 2022

Trial Snapshot

Phase: Phase 1
Status: Active, not recruiting
Sponsor: Aprea Therapeutics AB
Enrollment: 154

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional clinical trial of medicinal product

Eligibility Criteria

Sex: All

Inclusion Criteria

•1. Patient has signed the Informed Consent (ICF) and is able to comply with protocol requirements
•2. Documented diagnosis of MDS, according to WHO classification (<20% blasts), that meets IPSS-R classification of intermediate, high, or very high-risk disease
•3. Patient has adequate organ function as defined by the following laboratory values:
•a) Creatinine clearance > 30 mL/min (by Cockcroft-Gault method; see Appendix IV)
•b) Total serum bilirubin < 1.5 × ULN unless due to Gilbert’s Syndrome, underlying disease of MDS, hemolysis or considered an effect of regular blood transfusions
•c) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN, unless due to underlying disease of MDS
•4. Age =18 years at the time of signing the informed consent form (ICF)
•5. Having at least one TP53 mutation which is not benign or likely benign
•6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2
•7. Females of childbearing potential: negative pre-treatment urine or serum pregnancy test
•8. Females of childbearing potential and males with female partners of childbearing potential must be willing to use an effective form of contraception such as latex condom, hormonal birth control, intrauterine device or double barrier method during chemotherapy treatment and for at least six months thereafter
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 38
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 116

Exclusion Criteria

•1. Patient has a known history of HIV or active hepatitis B or active hepatitis C infection (testing not mandatory).
•2. Patient has any of the following cardiac abnormalities (as determined by treating MD):
•a) Myocardial infarction within six months prior to registration,
•b) New York Heart Association Class III or IV heart failure (see Appendix III) or known left ventricular ejection fraction (LVEF) < 40%, as assessed by echocardiogram or MUGA scan;
•c) A history of familial long QT syndrome,
•d) Symptomatic atrial or ventricular arrhythmias not controlled by medications
•e) QTc = 470 msec calculated from a mean of 3 ECG readings using Fridericia’s correction (QTcF = QT/RR0.33). Note: Patients with QTcF = 470 msec and with bundle branch block and/or pacemaker rhythm may be enrolled after approval by Medical Monitor.
•3. Concomitant malignancies or previous malignancies with less than a 1-year disease free interval at the time of signing consent. Patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis.
•4. Prior exposure to azacitidine, decitabine or investigational hypomethylating agent or induction chemotherapy for MDS or AML. Note: intensive chemotherapy for any other prior cancer is not exclusionary.
•5. Use of cytotoxic chemotherapeutic agents, or experimental agents (agents that are not commercially available) for the treatment of MDS within 14 days of the first day of study drug treatment.
•6. Concurrent use of erythroid stimulating agents, G-CSF, or GM-CSF within 14 days of the first day of study drug treatment.
•7. History of allogeneic stem cell transplantation
•8. Pregnancy: Pregnant women are excluded from this study because APR-246 has not been studied in pregnant patients.Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with APR-246, breastfeeding should be discontinued if the mother is treated with APR-246.
•9.Active uncontrolled infection.

Investigators

Sponsor

Aprea Therapeutics AB

Similar Trials

Active, not recruiting

Phase 1

Switch to MK-1439A (once a day) from a Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjectsHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862

EUCTR2014-005550-18-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.660

Active, not recruiting

Phase 1

Switch to MK-1439A from Ritonavir-boosted Protease Inhibitor regimen in HIV-1 infected subjectsHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862

EUCTR2014-005550-18-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.660

Active, not recruiting

Phase 1

EUCTR2014-005550-18-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.660

Active, not recruiting

Phase 1

Switch to MK-1439A (once a day) from a Ritonavir-boosted ProteaseInhibitor regimen in HIV-1 infected subjectsHuman Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862

EUCTR2014-005550-18-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.660

Active, not recruiting

Phase 1

EUCTR2014-005550-18-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.660